JP2017214416A5 - - Google Patents

Download PDF

Info

Publication number
JP2017214416A5
JP2017214416A5 JP2017157334A JP2017157334A JP2017214416A5 JP 2017214416 A5 JP2017214416 A5 JP 2017214416A5 JP 2017157334 A JP2017157334 A JP 2017157334A JP 2017157334 A JP2017157334 A JP 2017157334A JP 2017214416 A5 JP2017214416 A5 JP 2017214416A5
Authority
JP
Japan
Prior art keywords
group
alkyl
divalent
sulfonamide
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017157334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017214416A (ja
JP6602351B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017214416A publication Critical patent/JP2017214416A/ja
Publication of JP2017214416A5 publication Critical patent/JP2017214416A5/ja
Application granted granted Critical
Publication of JP6602351B2 publication Critical patent/JP6602351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017157334A 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用 Active JP6602351B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773773P 2013-03-06 2013-03-06
US61/773,773 2013-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015561536A Division JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Publications (3)

Publication Number Publication Date
JP2017214416A JP2017214416A (ja) 2017-12-07
JP2017214416A5 true JP2017214416A5 (enExample) 2019-01-31
JP6602351B2 JP6602351B2 (ja) 2019-11-06

Family

ID=50382628

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015561536A Active JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157335A Active JP6496786B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157334A Active JP6602351B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2019043934A Active JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015561536A Active JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157335A Active JP6496786B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019043934A Active JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Country Status (20)

Country Link
US (3) US9850264B2 (enExample)
EP (2) EP2964213B1 (enExample)
JP (4) JP6196327B2 (enExample)
KR (2) KR102227201B1 (enExample)
CN (2) CN105007909B (enExample)
AR (1) AR095034A1 (enExample)
AU (3) AU2014225992B2 (enExample)
BR (2) BR112015021371B1 (enExample)
CA (2) CA2898301C (enExample)
CL (3) CL2015002485A1 (enExample)
ES (2) ES3036990T3 (enExample)
IL (3) IL241012B (enExample)
MX (2) MX393070B (enExample)
MY (1) MY207109A (enExample)
PH (3) PH12020500285B1 (enExample)
RU (2) RU2663911C2 (enExample)
SG (2) SG10201801471RA (enExample)
TW (1) TWI616200B (enExample)
WO (1) WO2014138037A1 (enExample)
ZA (1) ZA201505134B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040145T2 (hu) * 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
SG11201406629VA (en) * 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
EP2850058B1 (en) 2012-05-16 2016-07-13 Actelion Pharmaceuticals Ltd. 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
AU2014226001B2 (en) 2013-03-06 2018-12-06 Allergan, Inc. Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases
EP2964213B1 (en) * 2013-03-06 2020-11-04 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
KR102313757B1 (ko) * 2013-07-16 2021-10-18 알러간, 인코포레이티드 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체
BR112016001106A8 (pt) 2013-07-18 2017-12-26 Actelion Pharmaceuticals Ltd Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
KR20170005121A (ko) 2014-05-21 2017-01-11 알러간, 인코포레이티드 폼일 펩타이드 수용체 조절제로서의 이미다졸 유도체
EP3271327A4 (en) 2015-03-19 2018-11-21 University of Maryland, Baltimore Runx2 transcription factor inhibitors and uses thereof
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
AU2017241767B2 (en) * 2016-03-28 2021-07-22 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators
WO2017180323A1 (en) * 2016-04-12 2017-10-19 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
TWI746660B (zh) 2016-10-06 2021-11-21 日商第一三共股份有限公司 尿素衍生物及其用途
CN109134533B (zh) 2017-06-27 2020-08-11 维眸生物科技(上海)有限公司 一种含磷化合物及其制备和应用
CN107814773B (zh) * 2017-11-13 2020-05-22 西安交通大学 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用
RU2712229C2 (ru) * 2018-05-17 2020-01-27 Закрытое акционерное общество "Институт экспериментальной фармакологии" Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.
JP2022151437A (ja) * 2021-03-26 2022-10-07 均 石井 網膜炎治療薬。
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases
WO2025239980A1 (en) * 2024-05-13 2025-11-20 University Of Virginia Patent Foundation Compounds for the inhibition of kifc3, methods of making the same, and pharmaceutical compositions comprising the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
JPS63232846A (ja) 1987-03-20 1988-09-28 Haruo Ogura 新規な固定相担体
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
CA2495284A1 (en) 2002-09-05 2004-03-18 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
US7943137B2 (en) * 2002-11-07 2011-05-17 Takeda Pharmaceutical Company Limited FPRL1 ligands and use thereof
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20080008694A1 (en) * 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
EP2492278A1 (en) * 2006-09-18 2012-08-29 Compugen Ltd. Antibodies against an agonist of G-protein coupled receptors and its use indiagnosis and therapy
EP2242747A1 (de) 2008-02-07 2010-10-27 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
WO2012109544A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US20120329873A1 (en) 2011-06-17 2012-12-27 Li yong-xin D-serine for the treatment of visual system disorders
EP2731931A1 (en) 2011-07-11 2014-05-21 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
HUE040145T2 (hu) * 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2814815A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
SG11201406629VA (en) 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
EP2964213B1 (en) 2013-03-06 2020-11-04 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

Similar Documents

Publication Publication Date Title
JP2018009012A5 (enExample)
JP2017214418A5 (enExample)
JP2017214417A5 (enExample)
JP2017066164A5 (enExample)
JP2011190260A5 (enExample)
JP2015063518A5 (ja) 有機化合物
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
BR112015005331B8 (pt) Eletrólito de polímero em gel e dispositivo eletroquímico incluindo o mesmo
JP2015527363A5 (enExample)
NZ734896A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
AR095339A1 (es) Compuestos moduladores alostericos de la hemoglobina
JP2013010731A5 (ja) 複素環化合物
EA200901167A1 (ru) Бициклические органические соединения, пригодные для лечения воспалительных и аллергических состояний
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
BR112015032689A2 (pt) composto heterocíclico fundido e uso em controle de pragas do mesmo
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
BRPI0910871A2 (pt) derivados espirocíclicos como inibidores de histona desacetilase
AR054814A1 (es) Derivados de piridazina
EA201100368A1 (ru) Амидные соединения, полезные в терапии
JP2013060411A5 (ja) カルバゾール化合物
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
JP2016529235A5 (enExample)
RU2014107744A (ru) Амидиновое соединение или его соль
JP2019500319A5 (enExample)
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина